Vitamin K2 reported to decrease disease activity in rheumatoid arthritis
The important biological activity that Vitamin K has in bone metabolism has already been supported by many studies. Particularly, Vitamin K2 has been shown in human clinical studies to improve bone strength and bone mass, making it a potentially effective treatment for osteoporosis and a preventive agent against fractures. More recently, it has been found that Vitamin K2 is able to decrease disease activity in rheumatoid arthritis (RA). Results of a cross-sectional, case-control study that was conducted in Saudi Arabia have recently been published in J Bone Miner Metab.
The researchers enrolled 42 patients with RA and 40 healthy controls for the purpose of evaluating the possible role of Vitamin K1 and Vitamin K2 as potential biomarkers for disease activity in patients with rheumatoid arthritis. They measured clinical articular features, serum levels of Vitamin K1 and K2 (MK-4 and MK-7 form) and different biochemical markers. This study has revealed that serum levels of Vitamin K1 and K2 were reduced in RA patients. Moreover, Vitamin K2 levels were moderately to strongly inversely correlated with the clinical articular features in RA patients, whereas Vitamin K1 levels were weakly correlated.
“The results of this study confirm the role of Vitamin K deficiency in the etiology of RA, and suggest that serum levels of Vitamin K1 and K2 may be considered as potential biomarkers for disease activity. Moreover, these results may support the use of Vitamin K in the treatment and early prophylaxis of RA” says Dr. Katarzyna Maresz, president of the International Science and Health Foundation. “However, Vitamin K2 seems to be a better choice to decrease disease activity,” Dr. Maresz emphasizes. “And larger scale clinical investigations may be necessary to confirm this new findings,” she adds.
Khojah, H.M., Ahmed, S., Abdel-Rahman, M.S. et al. Vitamin K homologs as potential biomarkers for disease activity in patients with rheumatoid arthritis. J Bone Miner Metab (2016). First Online: 08 October 2016. doi:10.1007/s00774-016-0785-4